Editorial: Kidney Cancer—A Unique Opportunity for the Development of Disease Specific Therapy
- 1 December 2002
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 168 (6) , 2411-2412
- https://doi.org/10.1016/s0022-5347(05)64156-0
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndromeCancer Cell, 2002
- Two HIFs may be better than oneCancer Cell, 2002
- Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell TransplantationNew England Journal of Medicine, 2000
- Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau proteinNature Cell Biology, 2000
- VHL: A very hip ligaseProceedings of the National Academy of Sciences, 1999
- Rising Incidence of Renal Cell Cancer in the United StatesJAMA, 1999
- Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomasNature Genetics, 1997
- Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report.Journal of Clinical Oncology, 1994
- Mutations of the VHL tumour suppressor gene in renal carcinomaNature Genetics, 1994
- Identification of the von Hippel-Lindau Disease Tumor Suppressor GeneScience, 1993